Pre-made Gancotamab benchmark antibody ( scFv, anti-ERBB2/HER2 therapeutic antibody, Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gancotamab, an antibody directed nanotherapeutic that encapsulates doxorubicin in a HER2-targeted liposome, that was being developed by Merrimack.
| Products Name (INN Index) | Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
|---|---|
| INN Name | Gancotamab |
| Target | ERBB2 |
| Format | scFv |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Merrimack Pharmaceuticals,HERMES BioSciences |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Breast cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ERBB2 |
| Package |
